Anti-Mouse PD-L2 (B7-DC) (Clone TY25) – Purified in vivo PLATINUM™ Functional Grade

Anti-Mouse PD-L2 (B7-DC) (Clone TY25) – Purified in vivo PLATINUM™ Functional Grade

Product No.: C9222

[product_table name="All Top" skus="C2292"]

- -
- -
Clone
TY25
Target
PD-L2
Formats AvailableView All
Product Type
Monoclonal Antibody
Alternate Names
PD-L2 , CD273, B7-DC
Isotype
Rat IgG2a κ
Applications
FC
,
IHC FF
,
in vivo
,
IP
,
WB

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Mouse
Host Species
Rat
Recommended Isotype Controls
Recommended Dilution Buffer
Immunogen
Purified transfected mouse B7-DC cell line
Product Concentration
≥ 5.0 mg/ml
Endotoxin Level
≤ 0.5 EU/mg as determined by the LAL method
Purity
≥98% monomer by analytical SEC
>95% by SDS Page
Formulation
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Product Preparation
Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Pathogen Testing
To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM<sup>TM</sup> antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.
Storage and Handling
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
USA
Shipping
Next Day 2-8°C
Applications and Recommended Usage?
Quality Tested by Leinco
FC The suggested concentration for this CD273 antibody clone TY25 for staining cells in flow cytometry is ≤ 0.25 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application.
WB
Additional Applications Reported In Literature ?
IHC FF
IP
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Description

Specificity
Clone TY25 recognizes an epitope on mouse PD-L2. TY25 does not cross-react with PD-L1.
Background
PD-L2 antibody, clone TY25, recognizes mouse programmed death ligand 2 (PDL-2), also known as B7-DC and CD273. PD-L2 is a 42 kDa type I transmembrane glycoprotein that belongs to the B7 family of the immunoglobulin (Ig) receptor superfamily. PD-L2 is an inhibitory ligand primarily expressed on antigen-presenting cells, including macrophages and a subset of dendritic cells (DCs). Its receptor, PD-1, is expressed by CD4-CD8- thymocytes as well as CD4 and CD8 T cells, monocytes, DCs, and B cells upon activation1. Binding of PD-L2 to PD-1 on CD4 and CD8 T cells inhibits T cell receptor (TCR) signaling, negatively regulating T cell proliferation, cytokine production, and cytotoxic activity2. PD-L2 is expressed on many tumor types3,4 and is associated with unfavorable prognosis in patients with solid tumors5.
Antigen Distribution
PD-L2 is expressed on macrophages and a subset of dendritic cells (DCs).
Ligand/Receptor
PD-1, uncharacterized receptor
PubMed
NCBI Gene Bank ID
Research Area
Costimulatory Molecules
.
Immunology

Leinco Antibody Advisor

Powered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments.

Clone TY25, a rat IgG2a monoclonal antibody targeting mouse PD-L2 (programmed death ligand 2, also known as B7-DC or CD273), is primarily used in blocking studies to investigate immune checkpoint interactions in vivo. The antibody has been specifically reported to block PD-1 mediated interactions when administered to mice.

Primary Research Applications

The most common in vivo application of clone TY25 is PD-1/PD-L2 pathway blockade to study immune regulation. PD-L2 naturally binds to its receptor PD-1, which is found on CD4 and CD8 thymocytes as well as activated T and B lymphocytes and myeloid cells. This interaction leads to inhibition of TCR-mediated T cell proliferation and cytokine production. By blocking this pathway with TY25, researchers can investigate the functional consequences of PD-L2-mediated immune suppression in various disease models.

Clone TY25 is also occasionally used for depleting or detecting PD-L2-expressing cells in mouse models. Since PD-L2 is expressed on monocytes, macrophages, and subsets of dendritic cells, the antibody enables researchers to manipulate or track these antigen-presenting cell populations in vivo.

Technical Specifications for In Vivo Use

The antibody is manufactured specifically for in vivo research with strict quality controls, including endotoxin levels below 1.0 EU/mg, and some formulations achieving less than 0.5 EU/mg. It demonstrates high purity (≥95-98% monomer by analytical SEC) and does not cross-react with PD-L1, ensuring specificity in experimental systems. The antibody is produced in animal-free facilities using in vitro cell culture techniques, making it suitable for sensitive in vivo experiments where contamination could confound results.

Based on the available search results, specific information about antibodies or proteins commonly used with TY25 in the literature is not provided. The search results mention TY25 as an anti-mouse PD-L2 (B7-DC) antibody, but they do not detail which other antibodies or proteins are frequently used alongside it in research studies.

TY25 is identified as an antibody targeting CD273 (also known as PD-L2 or B7-DC), which is part of the B7 family of immune checkpoint molecules. While the search results reference various immune-related antibodies and proteins in other contexts—such as anti-CD25 antibodies, anti-PD-1 antibodies, and other checkpoint molecules—these are not specifically linked to co-usage with TY25 in the literature.

To obtain comprehensive information about antibodies and proteins commonly paired with TY25 in experimental protocols or research publications, you would need to consult primary research articles or specialized immunology databases that specifically discuss PD-L2/B7-DC research applications.

Key Findings from Clone TY25 Citations in Scientific Literature

Clone TY25 is a monoclonal antibody used for targeting Mouse PD-L2. Key findings from its citations in scientific literature focus on its utility in immunology research:

  1. Immunology and Cell Differentiation: Clone TY25 is used as a marker for studying structural variations in T cell surface antigens, particularly important in immunology and cell differentiation studies.

  2. Protein-Protein Interaction Studies: It plays a significant role in bacterial two-hybrid interaction systems, which are used to study protein-protein interactions.

  3. Multiplexed Assays: Clone TY25 is often mentioned alongside other clones like F4/80 and CD62L, indicating its use in multiplexed assays to characterize immune cells.

  4. Validation and Use: The antibody is validated for various techniques such as FACS (Flow Cytometry) and Western Blotting, and is applied in research involving mouse models.

Overall, Clone TY25 is recognized for its versatility in immunological research, facilitating the study of immune cell interactions and differentiation.

Dosing Regimens of Clone TY25 (Anti-Mouse PD-L2) in Mouse Models

Current Knowledge on TY25 Dosing

There is no standardized dosing regimen for clone TY25 (anti-mouse PD-L2, also known as anti-CD273/B7-DC) in in vivo mouse models. Unlike other commonly used antibodies such as anti-CTLA-4 (clone 9H10 or 9D9), anti-CD4 (GK1.5), or anti-CD8 (2.43), there are no peer-reviewed guidelines or widely accepted dose ranges for TY25 in therapeutic or experimental mouse studies.

Flow Cytometry Staining Guidance

For flow cytometry applications, the manufacturer suggests using ≤ 0.25 μg per 10⁶ cells in a volume of 100 μl, with titration recommended for optimal performance in each application. However, this guidance is for in vitro staining, not for in vivo administration.

In Vivo Use: Lack of Consensus

For in vivo studies, each investigator must empirically determine the optimal dose based on their specific experimental model, endpoint, and antibody lot. This is in stark contrast to better-characterized antibodies, where "complete in vivo antibody dosing guides" provide standard ranges (e.g., 100–250 μg per mouse for anti-CTLA-4, 200–250 μg per mouse for anti-CD4, etc.). The lack of published data on TY25 suggests that its use in vivo is uncommon or confined to specialized research contexts.

Comparison Table: TY25 vs. Other Common Antibodies

AntibodyTargetStandard In Vivo DoseScheduleNotes
TY25PD-L2Not standardizedNot establishedDose determined empirically; no consensus in literature
9H10/9D9CTLA-4100–250 μg/mouseEvery 3 daysWidely used, peer-reviewed dosing
GK1.5CD4200–250 μg/mouse2–3 times/weekStandardized, used for depletion
2.43CD8250 μg/mouse2–3 times/weekStandardized, used for depletion

Recommendations for Researchers

  • Empirical Determination: If using TY25 in vivo, conduct pilot dose-finding experiments tailored to your specific mouse model, tumor type, and therapeutic goal.
  • Consult Manufacturer Data: Check the lot-specific datasheet for any updated recommendations, as information can vary by batch.
  • Benchmarking: Consider referencing dosing schemes from related checkpoint inhibitors (e.g., anti-PD-1, anti-CTLA-4) as a starting point, but adjust for differences in target biology, pharmacokinetics, and efficacy.
  • Report Practices: When publishing, clearly document the dosing regimen used to facilitate reproducibility and future meta-analyses.

Conclusion

Dosing regimens for clone TY25 in mouse models are not established in the literature or by consensus—in stark contrast to other immunomodulatory antibodies. Each laboratory must determine appropriate doses empirically, guided by experimental objectives and pilot data. The lack of standardization underscores the need for further preclinical characterization of this antibody.

References & Citations

1. Francisco LM, et al. (2010) Immunol Rev. 236:219-242
2. Latchman Y, et al. (2001) Nat Immunol. 2(3):261-8
3. Ahmad SM, et al. (2018) Oncoimmunology. 7:e1390641
4. Panjwani PK, et al. (2018) Hum Pathol. 71:91–9
5. Yang H, et al. (2019) Front Oncol. 9:47
Flow Cytometry
IHC FF
in vivo Protocol
Immunoprecipitation Protocol
General Western Blot Protocol

Certificate of Analysis

- -
- -

Formats Available

- -
- -
Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.